Cochrane · systematic review · CD009300
Complement inhibitors for age‐related macular degeneration
Tzoumas, N, Riding, G, Williams, MA, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
28
current version
GRADE rated
22
No studies
4
Included studies
NR
No studies 4 · 14.3%Ungraded 2 · 7.1%Very low 0 · 0%Low 2 · 7.1%Moderate 12 · 42.9%High 8 · 28.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings 1: Efficacy and safety of IVT lampalizumab 4‐weekly (monthly) versus sham for geographic atrophy (GA)
Population: adults with GA due to AMD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in BCVA from baseline at 1 year (ETDRS letters) Summary of findings 1: Efficacy and safety of IVT lampalizumab 4‐weekly (monthly) vs sham | no estimate extracted | 3 studies · 1182 participants | High |
Change in untransformed GA lesion size from baseline at 1 year (mm²) Summary of findings 1: Efficacy and safety of IVT lampalizumab 4‐weekly (monthly) vs sham | no estimate extracted | 3 studies · 1199 participants | Moderate Downgraded: imprecision |
Safety: Development of macular neovascularisation or exudative AMD at 1 year Summary of findings 1: Efficacy and safety of IVT lampalizumab 4‐weekly (monthly) vs sham | RR 1.77 [0.73, 4.3] | 3 studies · 1330 participants | Low Downgraded: imprecision |
Safety: Development of endophthalmitis at 1 year Summary of findings 1: Efficacy and safety of IVT lampalizumab 4‐weekly (monthly) vs sham | RR 6.92 [0.36, 133.73] | 3 studies · 1330 participants | Moderate Downgraded: imprecision |
Loss of ≥ 15 letters BCVA at 1 year Summary of findings 1: Efficacy and safety of IVT lampalizumab 4‐weekly (monthly) vs sham | RR 0.86 [0.63, 1.18] | 2 studies · 1103 participants | Moderate Downgraded: imprecision |
Change in LLVA from baseline at 1 year (ETDRS letters) Summary of findings 1: Efficacy and safety of IVT lampalizumab 4‐weekly (monthly) vs sham | no estimate extracted | 2 studies · 1068 participants | High |
Change in quality of life at 1 year (NEI VFQ‐25 composite score) Summary of findings 1: Efficacy and safety of IVT lampalizumab 4‐weekly (monthly) vs sham | no estimate extracted | 2 studies · 983 participants | High |
Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) versus sham for geographic atrophy (GA)
Population: adults with GA due to AMD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in BCVA from baseline at 1 year (ETDRS letters) Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham | no estimate extracted | 3 studies · 1184 participants | High |
Change in untransformed GA lesion size from baseline at 1 year (mm²) Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham | no estimate extracted | 3 studies · 1207 participants | High |
Safety: Development of macular neovascularisation or exudative AMD at 1 year Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham | RR 1.7 [0.67, 4.28] | 3 studies · 1331 participants | Low Downgraded: imprecision, inconsistency |
Safety: Development of endophthalmitis at 1 year Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham | RR 4.94 [0.24, 102.78] | 3 studies · 1331 participants | Moderate Downgraded: imprecision, inconsistency |
Loss of ≥ 15 letters BCVA at 1 year Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham | RR 0.98 [0.72, 1.33] | 2 studies · 1096 participants | Moderate Downgraded: imprecision, inconsistency |
Change in LLVA from baseline at 1 year (ETDRS letters) Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham | no estimate extracted | 2 studies · 1065 participants | High |
Change in quality of life at 1 year (NEI VFQ‐25 composite score) Summary of findings 2: Efficacy and safety of IVT lampalizumab 6‐ to 8‐weekly (every other month) vs sham | no estimate extracted | 2 studies · 1003 participants | Moderate Downgraded: imprecision, inconsistency |
Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) versus sham for geographic atrophy (GA)
Population: adults with GA due to AMD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in BCVA from baseline at 1 year (ETDRS letters) Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham | no estimate extracted | 1 study · 164 participants | Moderate Downgraded: imprecision, inconsistency |
Change in untransformed GA lesion size from baseline at 1 year (mm²) Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham | no estimate extracted | 3 studies · 967 participants | High |
Safety: Development of macular neovascularisation or exudative AMD at 1 year Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham | RR 4.47 [0.41, 48.98] | 3 studies · 1003 participants | Ungraded |
Safety: Development of endophthalmitis at 1 year Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham | RR 3.79 [0.42, 34.05] | 3 studies · 1003 participants | Moderate Downgraded: imprecision, inconsistency |
Loss of ≥ 15 letters BCVA at 1 year Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham | no estimate extracted | NR | No studies |
Change in LLVA from baseline at 1 year (ETDRS letters) Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham | no estimate extracted | 1 study · 164 participants | Moderate Downgraded: imprecision, inconsistency |
Change in quality of life at 1 year (NEI VFQ‐25 composite score) Summary of findings 3: Efficacy and safety of IVT pegcetacoplan 4‐weekly (monthly) vs sham | no estimate extracted | NR | No studies |
Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) versus sham for geographic atrophy (GA)
Population: adults with GA due to AMD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in BCVA from baseline at 1 year (ETDRS letters) Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham | no estimate extracted | 1 study · 158 participants | Moderate Downgraded: imprecision, inconsistency |
Change in untransformed GA lesion size from baseline at 1 year (mm²) Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham | no estimate extracted | 3 studies · 963 participants | High |
Safety: Development of macular neovascularisation or exudative AMD at 1 year Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham | RR 2.29 [0.46, 11.35] | 3 studies · 997 participants | Ungraded |
Safety: Development of endophthalmitis at 1 year Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham | RR 4.77 [0.55, 41.68] | 3 studies · 997 participants | Moderate Downgraded: imprecision, inconsistency |
Loss of ≥ 15 letters BCVA at 1 year Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham | no estimate extracted | NR | No studies |
Change in LLVA from baseline at 1 year (ETDRS letters) Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham | no estimate extracted | 1 study · 158 participants | Moderate Downgraded: imprecision, inconsistency |
Change in quality of life at 1 year (NEI VFQ‐25 composite score) Summary of findings 4: Efficacy and safety of IVT pegcetacoplan 8‐weekly (every other month) vs sham | no estimate extracted | NR | No studies |